Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $461.39 Consensus Target Price from Brokerages

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-six research firms that are presently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $455.3065.

ALNY has been the topic of several research analyst reports. Wall Street Zen lowered Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 7th. Truist Financial dropped their target price on shares of Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating for the company in a research report on Monday. Chardan Capital reaffirmed a “buy” rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Wells Fargo & Company boosted their price objective on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research note on Friday, May 1st. Finally, Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 4th.

Alnylam Pharmaceuticals Trading Down 0.8%

ALNY stock opened at $279.14 on Thursday. The company has a market cap of $37.27 billion, a price-to-earnings ratio of 76.27 and a beta of 0.27. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. The business has a fifty day simple moving average of $294.97 and a 200-day simple moving average of $322.32. Alnylam Pharmaceuticals has a 52 week low of $273.11 and a 52 week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The firm had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter last year, the firm earned ($0.44) earnings per share. The firm’s revenue for the quarter was up 96.4% compared to the same quarter last year. On average, equities research analysts expect that Alnylam Pharmaceuticals will post 7.26 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares in the company, valued at approximately $473,302.76. This represents a 70.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.86% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Large investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. raised its holdings in shares of Alnylam Pharmaceuticals by 20.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 155,695 shares of the biopharmaceutical company’s stock valued at $46,869,000 after buying an additional 26,799 shares during the period. Parallel Advisors LLC boosted its holdings in Alnylam Pharmaceuticals by 7.9% in the 1st quarter. Parallel Advisors LLC now owns 891 shares of the biopharmaceutical company’s stock worth $295,000 after acquiring an additional 65 shares during the period. Glenmede Trust Co. NA grew its position in Alnylam Pharmaceuticals by 8.3% in the first quarter. Glenmede Trust Co. NA now owns 731 shares of the biopharmaceutical company’s stock valued at $242,000 after acquiring an additional 56 shares in the last quarter. Groupama Asset Managment raised its stake in shares of Alnylam Pharmaceuticals by 2.5% during the first quarter. Groupama Asset Managment now owns 36,767 shares of the biopharmaceutical company’s stock valued at $12,165,000 after purchasing an additional 889 shares during the period. Finally, Segall Bryant & Hamill LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the first quarter valued at approximately $641,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.